Trials / Unknown
UnknownNCT02515734
A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab
A Randomized Phase II Study to Investigate the Deepness of Response of FOLFOXIRI Plus Cetuximab (Erbitux) Versus FOLFOXIRI Plus Bevacizumab as the First-line Therapy in Metastatic Colorectal Cancer Patients With RAS Wild-type Tumors: DEEPER
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- Sponsor
- Japan Clinical Cancer Research Organization · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors.
Detailed description
This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors. In this study the investigators employed deepness of response as a primary endpoint.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fluorouracil | |
| DRUG | Leucovorin | |
| DRUG | irinotecan | |
| DRUG | oxaliplatin | |
| BIOLOGICAL | bevacizumab | |
| BIOLOGICAL | cetuximab |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2017-12-01
- Completion
- 2020-06-01
- First posted
- 2015-08-05
- Last updated
- 2015-08-05
Source: ClinicalTrials.gov record NCT02515734. Inclusion in this directory is not an endorsement.